261 related articles for article (PubMed ID: 29152593)
1. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma.
Neel DS; Bivona TG
NPJ Precis Oncol; 2017; 1():. PubMed ID: 29152593
[TBL] [Abstract][Full Text] [Related]
2. Emerging treatment for advanced lung cancer with EGFR mutation.
Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
[TBL] [Abstract][Full Text] [Related]
3. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
4. RAS signaling in ALK fusion lung cancer.
Hrustanovic G; Bivona TG
Small GTPases; 2016; 7(1):32-3. PubMed ID: 26901483
[TBL] [Abstract][Full Text] [Related]
5. Collateral sensitivity networks reveal evolutionary instability and novel treatment strategies in ALK mutated non-small cell lung cancer.
Dhawan A; Nichol D; Kinose F; Abazeed ME; Marusyk A; Haura EB; Scott JG
Sci Rep; 2017 Apr; 7(1):1232. PubMed ID: 28450729
[TBL] [Abstract][Full Text] [Related]
6. ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options.
Steuer CE; Ramalingam SS
Cancer; 2014 Aug; 120(16):2392-402. PubMed ID: 24853389
[TBL] [Abstract][Full Text] [Related]
7. Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Curr Clin Pharmacol; 2016; 11(2):77-87. PubMed ID: 27138017
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.
Facchinetti F; Proto C; Minari R; Garassino M; Tiseo M
Handb Exp Pharmacol; 2018; 249():63-89. PubMed ID: 28332047
[TBL] [Abstract][Full Text] [Related]
9. EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.
Tulchinsky E; Demidov O; Kriajevska M; Barlev NA; Imyanitov E
Biochim Biophys Acta Rev Cancer; 2019 Jan; 1871(1):29-39. PubMed ID: 30419315
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Chung C
J Oncol Pharm Pract; 2016 Jun; 22(3):461-76. PubMed ID: 25855240
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors.
Pathak A; Rajappa S; Gore A
Indian J Cancer; 2017 Dec; 54(Supplement):S1-S8. PubMed ID: 29292702
[TBL] [Abstract][Full Text] [Related]
12. Successes and limitations of targeted cancer therapy in lung cancer.
Suda K; Mitsudomi T
Prog Tumor Res; 2014; 41():62-77. PubMed ID: 24727987
[TBL] [Abstract][Full Text] [Related]
13. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.
Hrustanovic G; Olivas V; Pazarentzos E; Tulpule A; Asthana S; Blakely CM; Okimoto RA; Lin L; Neel DS; Sabnis A; Flanagan J; Chan E; Varella-Garcia M; Aisner DL; Vaishnavi A; Ou SH; Collisson EA; Ichihara E; Mack PC; Lovly CM; Karachaliou N; Rosell R; Riess JW; Doebele RC; Bivona TG
Nat Med; 2015 Sep; 21(9):1038-47. PubMed ID: 26301689
[TBL] [Abstract][Full Text] [Related]
14. Cell death in cancer therapy of lung adenocarcinoma.
Zagryazhskaya A; Gyuraszova K; Zhivotovsky B
Int J Dev Biol; 2015; 59(1-3):119-29. PubMed ID: 26374533
[TBL] [Abstract][Full Text] [Related]
15. Targeted Therapies in Cancer: To Be or Not to Be, Selective.
Montoya S; Soong D; Nguyen N; Affer M; Munamarty SP; Taylor J
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829820
[TBL] [Abstract][Full Text] [Related]
16. ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Chuang JC; Stehr H; Liang Y; Das M; Huang J; Diehn M; Wakelee HA; Neal JW
J Thorac Oncol; 2017 May; 12(5):833-842. PubMed ID: 28167203
[TBL] [Abstract][Full Text] [Related]
17. Resistance to Therapy.
Rivera G; Wakelee HA
Cancer Treat Res; 2016; 170():183-202. PubMed ID: 27535395
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Breast Cancer Kinome.
Miller SM; Goulet DR; Johnson GL
J Cell Physiol; 2017 Jan; 232(1):53-60. PubMed ID: 27186656
[TBL] [Abstract][Full Text] [Related]
19. ALK and crizotinib: after the honeymoon…what else? Resistance mechanisms and new therapies to overcome it.
Rolfo C; Passiglia F; Castiglia M; Raez LE; Germonpre P; Gil-Bazo I; Zwaenepoel K; De Wilde A; Bronte G; Russo A; Van Meerbeeck JP; Van Schil P; Pauwels P
Transl Lung Cancer Res; 2014 Aug; 3(4):250-61. PubMed ID: 25806308
[TBL] [Abstract][Full Text] [Related]
20. [Genomics of lung adenocarcinoma: pathogenetic significance and clinical applications.].
Palmirotta R; Acquafredda S; Argentiero A; Carella C; Lanotte L; Pappagallo N; Quaresmini D; Silvestris F
Recenti Prog Med; 2016 Dec; 107(12):652-672. PubMed ID: 27997009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
